Addition Therapeutics unveiled its Precise RNA‑Mediated Insertion of Transgenes (PRINT) platform and raised $106.5 million to advance all‑RNA, lipid nanoparticle (LNP)‑based gene insertion therapies. The startup is building on retrotransposon biology to enable durable genomic insertion without viral vectors. Company statements and launch materials describe a lipid nanoparticle delivery system paired with RNA‑encoded insertion machinery aimed at chronic and rare diseases. Addition’s financing will fund IND‑enabling work, manufacturing scale‑up, and early clinical programs. The company has attracted high‑profile investors and framed the approach as an alternative to AAV or DNA‑based gene therapy. Addition’s capital raise and scientific pivot highlight investor appetite for novel nonviral gene‑insertion strategies that could simplify manufacturing and repeat dosing. Key near‑term milestones include IND filings and demonstration of durable, targeted insertion with acceptable safety in preclinical models.